The McKinsey Quarterly Chart Focus Newsletter November 2004 | Member Edition |
| The sweet spot between focus and diversification |
 |
|
Focused companies generally outperform diversified ones, but moderately diversified companies do at least as well—and sometimes better. |

|
Financial markets tend to value focused companies more highly than diversified ones because investors believe that the former allocate capital more efficiently than do the latter. Nonetheless, companies must explore new opportunities in order to compensate for slower growth in mature businesses. Fortunately, a moderate path between pure focus and broad diversification offers a strategic sweet spot. Our analysis of 412 S&P 500 companies found that although focused ones outperformed their diversified counterparts as a group, those that were moderately diversified—earning at least 67 percent of their revenues from only two business segments—outperformed focused and broadly diversified companies in 81 percent of the three-year time periods we examined.
While the right strategic balance varies from one company to another, and managers must constantly refine the mixture to get the best results, the notion that focus is better isn't always borne out. For more on the specifics of our research, read "Are you too focused?"  |
| Also of interest |
 |
"A new look at diversification" (2004 Number 1), which examines the case of the basic-materials industry, supports the idea that diversified companies can outperform more focused ones.
"Multiple choice for the chemical industry" (2003 Number 3) reports that the most important driver of performance for the companies in it isn't scale, geography, or market position but, rather, the way they manage their business portfolios.
|
"What is the market telling you about your strategy?" (2000 Strategy Anthology) explains how performance affects a company's market valuation.
"Diversify with care" (2000 Special Edition: Europe in transition) examines the wave of new ventures spawned by the deregulation of Europe's energy utilities, few of which managed to create value.
|
| Did you miss last month's Chart Focus? |
 |
The risk premium in vaccines
Vaccine researchers are making progress battling the world's most dangerous diseases, but the risks involved in delivering drugs to developing nations, which need them sorely, are high. Partnerships among pharmaceutical companies, governments, and other organizations can keep the research and delivery pipelines flowing.
|
|